Janux Therapeutics price target raised to $82 from $62 at BTIG

BTIG analyst Justin Zelin raised the firm’s price target on Janux Therapeutics (JANX) to $82 from $62 and keeps a Buy rating on the shares. The firm sees “attractive risk-reward” heading into a catalyst, noting that the updated JANX007 data to be released by mid-December should confirm the initial safety/efficacy profile as well as provide initial reads on durability, the analyst tells investors in a research note.